These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 17082468

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.
    Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, Wasser D, Johnson-Traver S, Lochhead J, Ziolwolski C.
    Arch Neurol; 2005 May; 62(5):753-7. PubMed ID: 15883262
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. AMPA potentiator treatment of cognitive deficits in Alzheimer disease.
    Chappell AS, Gonzales C, Williams J, Witte MM, Mohs RC, Sperling R.
    Neurology; 2007 Mar 27; 68(13):1008-12. PubMed ID: 17389305
    [Abstract] [Full Text] [Related]

  • 8. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.
    Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL.
    Arch Neurol; 2003 Dec 27; 60(12):1685-91. PubMed ID: 14676042
    [Abstract] [Full Text] [Related]

  • 9. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.
    Filip V, Kolibás E.
    J Psychiatry Neurosci; 1999 May 27; 24(3):234-43. PubMed ID: 10354658
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
    van der Vlies AE, Verwey NA, Bouwman FH, Blankenstein MA, Klein M, Scheltens P, van der Flier WM.
    Neurology; 2009 Mar 24; 72(12):1056-61. PubMed ID: 19307538
    [Abstract] [Full Text] [Related]

  • 15. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T.
    Arch Neurol; 2009 Mar 24; 66(3):382-9. PubMed ID: 19273758
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
    Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM.
    Arch Neurol; 2007 Mar 24; 64(3):343-9. PubMed ID: 17210801
    [Abstract] [Full Text] [Related]

  • 19. Galantamine protects against oxidative stress induced by amyloid-beta peptide in cortical neurons.
    Melo JB, Sousa C, Garção P, Oliveira CR, Agostinho P.
    Eur J Neurosci; 2009 Feb 24; 29(3):455-64. PubMed ID: 19222556
    [Abstract] [Full Text] [Related]

  • 20. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.
    Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, Demattos RB.
    Clin Neuropharmacol; 2010 Feb 24; 33(2):67-73. PubMed ID: 20375655
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.